Steven Yates, MD
Medical Oncology · Las Vegas, NVNPI 1609814417
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by US Oncology Corporate, Inc. at 40.3% of the total. Reporting peaked in 2024 at $1,601 and has fallen 93.8% since, to $100 in 2025.
Across 29 payments — averaging $119.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Oncology Corporate, Inc.$1K
- Cardinal Health 108 LLC$468
- Sanofi$268
- EMD Serono, Inc.$230
- Regeneron Healthcare Solutions, Inc.$150
- Karyopharm Therapeutics Inc.$125
- plus $821 from 12 others
What the payments were for
- Consulting fees$2307%
- Travel & lodging$95728%
- Food & beverage$2,03959%
- Education$1956%
- Gifts$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Oncology Corporate, Inc. | 4 | $1,392 |
| Cardinal Health 108 LLC | 5 | $468 |
| Sanofi | 2 | $268 |
| EMD Serono, Inc. | 1 | $230 |
| Regeneron Healthcare Solutions, Inc. | 2 | $150 |
| Karyopharm Therapeutics Inc. | 1 | $125 |
| Verastem, Inc. | 1 | $124 |
| AstraZeneca | 1 | $122 |
| Astellas Pharma US Inc | 1 | $100 |
| Amgen | 1 | $95 |
| Gilead | 1 | $95 |
| Pfizer | 1 | $83 |
| AbbVie | 3 | $78 |
| GSK | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Seagen Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Bristol Myers Squibb | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 106 | $1,981,571 |
| ImbruvicaIbrutinib | 41 | $536,674 |
| JakafiRuxolitinib Phosphate | 29 | $518,841 |
| PomalystPomalidomide | 22 | $492,724 |
| IbrancePalbociclib | 31 | $487,559 |
| XtandiEnzalutamide | 32 | $452,313 |
| VerzenioAbemaciclib | 29 | $422,966 |
| LenvimaLenvatinib Mesylate | 15 | $356,323 |
| InrebicFedratinib Dihydrochloride | 12 | $318,528 |
| ErleadaApalutamide | 20 | $291,589 |
| CalquenceAcalabrutinib Maleate | 19 | $280,472 |
| Lenalidomide | 16 | $230,347 |
| BrukinsaZanubrutinib | 15 | $213,411 |
| VenclextaVenetoclax | 11 | $118,054 |
| Abiraterone Acetate | 22 | $35,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $19 | $2,300,099118 claims |
| PfizerIbrance | $83 | $487,55931 claims |
| Astellas Pharma US IncXtandi | $100 | $452,31332 claims |
| AstraZenecaCalquence | $122 | $280,47219 claims |
| AbbVieVenclexta | $78 | $118,05411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Las Vegas
- Fadi BraitehLas Vegas$2.7M
- Brian VicunaLas Vegas$107K
- Sandra LombardoLas Vegas$14K
- Deepa MocherlaLas Vegas$3K
- Claire HilesLas Vegas$918
- Okechukwu ObiLas Vegas$812
- Behrooz ShamlooLas Vegas$553
- Stephen IacoboniLas Vegas$477
- Swetha PentapatiLas Vegas$258
- Gary PalmerLas Vegas$86
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.